ARTICLE | Clinical News
Jublia efinaconazole regulatory update
June 16, 2014 7:00 AM UTC
Kaken's marketing partner Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) said FDA approved an NDA for Jublia efinaconazole to treat onychomycosis of the toenails. Th...